Compare VMET & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VMET | ABCL |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | Canada | Canada |
| Employees | 8 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | N/A | 2020 |
| Metric | VMET | ABCL |
|---|---|---|
| Price | $12.08 | $5.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.40 |
| AVG Volume (30 Days) | 157.7K | ★ 8.4M |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | $185.47 | N/A |
| Revenue Next Year | $16.05 | $21.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $9.10 | $2.45 |
| 52 Week High | $13.81 | $6.79 |
| Indicator | VMET | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 49.35 | 55.07 |
| Support Level | $10.85 | $5.34 |
| Resistance Level | $13.62 | $5.63 |
| Average True Range (ATR) | 0.79 | 0.56 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 50.14 | 56.84 |
Versamet Royalties Corp is a diversified metals royalty and streaming company with exposure to a range of resource royalties and streams including gold, silver, copper, zinc, graphite and uranium, across a variety of jurisdictions. The Company's operating segments are considered to be its individual royalties, streams and the Greenstone gold interest.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.